Overcoming Acquired Resistance through Combinatorial Therapy
Lung Cancer is the leading cause of cancer deaths in both males and females in the U.S. and worldwide. Conventional standards of care, including surgery, radiation, chemotherapy, and now, targeted therapy, provide only temporary benefits. Although molecular targeted monotherapies like tyrosine kinase inhibitors (TKIs) have improved patient survival, the majority of these FDA-approved therapies still result in acquired drug resistance in a relatively short period. One effective approach to address this need for ‘smarter therapies’ is the use of combination drug therapy; employing lower doses of two drugs whose combined effect is greater than either drug alone (synergy). The National Cancer Institute’s 2016 initiative to fund Precision Medicine, including combination therapies, is proof of the many advantages of combination therapy over monotherapy. Our goal is to investigate the use of combination targeted therapies that, when used in tandem, induce maximal death as an anti-cancer strategy.